



Apellis APL2-ALS-206 trial

In collaboration with our academic partner TRICALS, Apellis is conducting a Phase 2 trial to determine the safety and efficacy of their investigational drug pegcetacoplan for the treatment of ALS.

Pegcetacoplan

Pegcetacoplan (also known as APL2) has not previously been tested in people with ALS, but has been tested in previous trials in healthy volunteers and people with blood, kidney and eye diseases.

Researchers believe that the immune system is changed in people with ALS and that this contributes to nerve cell loss. Pegcetacoplan is designed to shut down the functioning of part of your immune system. Therefore, it is now being investigated whether pegcetacoplan can possibly prevent the loss of nerve cells.

All information on the study design, entry criteria and participating TRICALS centers can be found [here at the TRICALS website](#).

EUpALS

Kapucijnenvoer 33 B/1, B-3000 Leuven, Belgium
Tel: +32 (0)16-23 95 82 – Fax: +32 (0)16-29 98 65
info@ALS.eu – ALS.eu